# A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.

> **NCT04390334** · PHASE1 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Daridorexant
- **DRUG:** Famotidine
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT04390334
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-13
- **Primary completion:** 2020-06-26
- **Final completion:** 2020-06-26
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04390334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04390334, "A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04390334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*